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Atypical teratoid/rhabdoid tumors (AT/RT) are 
aggressively growing malignant embryonal neo-
plasms of the central nervous system (CNS), which 
mainly affect young children. Loss of SMARCB1/INI1 
(or SMARCA4/BRG1 in rare cases) is recognized as 
the genetic hallmark of AT/RTs. Furthermore, these 
tumors can be distinguished into three distinct DNA-
methylation based molecular subgroups (i.e. -MYC, 
-SHH and -TYR) (1–3). While most AT/RTs are consid-
ered to occur de novo, previous studies have recog-
nized secondary SMARCB1/INI1-deficient rhabdoid 
tumors arising from other low grade CNS tumors in 
young patients (4–9). Moreover, three AT/RTs, 
which harbored epigenetic and mutational charac-
teristics of pleomorphic xanthoastrocytoma (PXA), 
while being entirely void of nuclear SMARCB1/INI1 
expression were recently described in older children 
(10). We here report the first case of an AT/RT with 
molecular features of PXA in an older adult. 
A 62-year-old woman presented with diffuse 
headaches since several weeks. Medical examina-
tion revealed no clinically significant neurological 
deficits. An MRI showed a right-sided tumor in tem-
poromesial location with dimensions of 3.8 x 3.7 x 
4.1 cm. The tumor displayed contrast-enhancement, 
central necrosis und perifocal edema (Figure 1a). 
Additionally, a smaller lesion of the infundibulum 
was identified. Preoperative lumbar puncture with 
examination of cerebrospinal fluid revealed exten-
sive presence of tumor cells. The temporomesial tu-
mor was subtotally resected. 
Upon histopathological examination, we saw a 
highly cellular, partially necrotic tumor, which was 
entirely composed of pleomorphic rhabdoid cells 
with eosinophilic cytoplasms (Figure 1b). Gomori-
staining demonstrated a prominent reticulin net-
work (Figure 1c). Immunohistochemical staining
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Figure 1: Radiology, histopathology and epigenetic analysis. 
a) Representative axial MRI demonstrating the preoperative finding of a large temporomesial tumor (large arrow). Contrast enhancement 
was found partially within the tumor and additionally in the region of the infundibulum (small arrow). T1-weighted image plus contrast 
medium. 
b) Histomorphology revealed geographical necrosis, prominent rhabdoid morphology and brisk mitotic activity of tumor cells (inset).  
c) The tumor showed a prominent network of reticular fibres, visible in the Gomori silver impregnation. 
d) Immunostaining for vimentin was vastly strongly positive. 
e) Immunostaining for cytokeratins (AE1/3) was vastly strongly positive in the majority of tumor cells. 
f) Immunostaining for GFAP was negative in tumor cells while demarcating residual brain tissue.  
g) Ki67 proliferative index amounted to about 40%. 
h) Tumor cells exhibited loss of nuclear SMARCB1/INI1 staining. Retained nuclear staining was found in blood vessels and inflammatory 
cells (inset). Scale bar in b – h is 150 µm. 
i) Copy number profile of the tumor indicated a homozygous CDKN2A/B (short arrow) and SMARCB1/INI1 (long arrow) deletion. 
j) tSNE including a reference set of brain tumors (GSE90496, (11)) showed affiliation of the tumor to the group of PXA. 
Clicking the figure will lead you to the full virtual slide (H&E). 
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showed positivity for vimentin (Figure 1d) and cy-
tokeratin AE1/3 (PanCK, Figure 1e). GFAP was nega-
tive within the tumor cells (Figure 1f). Strong prolif-
eration was demonstrated by brisk mitotic activity 
and a proliferative index of 40% in the Ki67-staining 
(Figure 1g). SMARCB1/INI1 nuclear signal was con-
sistently lost in tumor cells (Figure 1h). Further im-
munohistochemical stainings are displayed in Sup-
plementary Figure 1. DNA was extracted from the 
tumor and subjected to DNA methylation profiling 
using the Illumina EPIC BeadChip array. Using the 
brain tumor methylation classifier (v11b4 and v12.3) 
(11), the tumor did not match with a defined meth-
ylation class (no calibrated score was ≥ 0.3). The 
copy number profile revealed a homozygous 
SMARCB1/INI1 and CDKN2A/B deletion, gains in 
chromosomes 2 and 7q as well as losses of chromo-
somes 9p, 14q, 16 and 22q (Figure 1i). T-SNE analysis 
displayed similarity of the case with PXA (Figure 1j). 
DNA panel sequencing confirmed a BRAF V600E mu-
tation (Table 1). Taking all diagnostic layers to-
gether, we saw a malignant rhabdoid tumor, not 
elsewhere classified, with BRAF V600E mutation, ho-
mozygous SMARCB1/INI1 and CDKN2A/B deletion, 
and a methylation profile with similarity to PXA. In 
correspondence with the provisional designation of 
Thomas et al. (10), the case was signed out as AT/RT 
with molecular features of PXA. Postoperative clini-
cal staging of the patient revealed a smaller lesion of 
uncertain dignity in the cervical myelon. No further 
malignancies outside of the CNS were found. Unfor-
tunately, the patient developed postoperative hemi-
plegia, infarctions of the basal ganglia and displayed 
progressive worsening of the clinical status. Pallia-
tive chemotherapy was administered with intrathe-
cal application of Methotrexate. The patient died in 
the 6th postoperative week. 
As it is the case for the herein presented tumor, 
it remains unclear, if AT/RTs with molecular features 
of PXA correspond to secondary rhabdoid tumors, 
which have emerged from and entirely outgrown 
preexisting PXAs. In contrast, such tumors might 
also occur independently from precursor lesions and 
therefore represent a distinct entity. Of note, the 
CNS WHO classification of 2016 has previously rec-
ognized high-grade rhabdoid components with loss 
of SMARCB1/INI1 in anaplastic PXAs and suggested 
the term “SMARCB1-deficient anaplastic PXA” for 
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such lesions (12). However, since the tumor pre-
sented here was entirely void of SMARCB1/INI1 re-
tained tumor cells and a preexisting lesion had not 
been described beforehand, the tumor’s origin is left 
to speculation. It is moreover important to note that 
the single genetic and epigenetic alterations we 
found are not pathognomonic for PXAs (13) and the 
tumor did not match with a defined methylation 
class of the brain tumor classifier. However, the 
combination of all molecular findings – including the 
epigenetic resemblance to PXAs via tSNE analysis – 
clearly demonstrates similarity with molecular fea-
tures of PXAs. 
A complicating aspect of the current and soon 
to be updated CNS WHO classification of 2016 is that 
SMARCB1/INI1-deficient rhabdoid brain tumors 
tend to be vastly designated as AT/RTs. The herein 
presented case exemplarily demonstrates that - es-
pecially without molecular investigations - this may 
lead to the subsumption of malignancies with vari-
ous epigenetic and mutational landscapes as well as 
different cellular origins. While the preceding sum-
mary of the new WHO classification of 2021 (14) has 
announced the recognition of epigenetic analyses in 
AT/RTs, it is currently still unclear how SMARCB1/ 
INI1-deficient brain tumors with rhabdoid morphol-
ogy and lack of epigenetic features of AT/RTs are to 
be classified. Future studies should evaluate if pre-
dictive and prognostic implications of these tumors 
call for a more concise classification and terminol-
ogy. 
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